New drug made available outside clinical trials for patients in need

NCT ID NCT07647627

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program allows certain patients to receive dibotatug (DR-01) even if they cannot join a clinical trial. It is only for those with a doctor's request and who meet specific criteria. The goal is to provide access to a potential treatment when no other options are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dibotatug (DR-01)

What this could lead to

If this program helps patients, it could provide early access to a potential treatment for those with no other options.

What could go wrong

This is an expanded access program, not a clinical trial, so there is no guarantee of benefit. Risks are not fully known and may include serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new related studies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••